Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01907165 · ClinicalTrials.gov registry record · Early Phase 1
Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
A Early Phase 1 study of Glioblastoma, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01907165: Completed Early Phase 1 study of Glioblastoma, sponsored by Washington University School of Medicine.
NCT01907165 is a Early Phase 1 study of Glioblastoma that has completed, run by Washington University School of Medicine. The registered enrollment target is 21 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01907165, a Early Phase 1 study of Glioblastoma, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies disulfiram in treating patients with glioblastoma multiforme (GBM) who have completed radiation therapy with temozolomide. Disulfiram may block some of the enzymes needed for tumor cell growth and improve clinical outcome in GBM patients.
Primary Outcome
Degree of proteasome inhibition in peripheral white blood cells and rate of complete inhibition in GBM patients using descriptive statistics
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Disulfiram
- DIETARY_SUPPLEMENT Copper gluconate
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-10-10 |
| Est. Completion | 2018-02-09 |
| Phase | Early Phase 1 |
What the finished NCT01907165 record still lists
NCT01907165 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT01907165 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT01907165 about?
NCT01907165 is a clinical study titled "Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide". This clinical trial studies disulfiram in treating patients with glioblastoma multiforme (GBM) who have completed radiation therapy with temozolomide. Disulfiram may block some of the enzymes needed for tumor cell growth and improve clinical outcome in GBM patients.
What is the current status of trial NCT01907165?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2013-10-10. Estimated completion is 2018-02-09.
What conditions does trial NCT01907165 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT01907165?
The interventions under investigation include: Temozolomide (DRUG), Disulfiram (DRUG), Copper gluconate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01907165?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01907165 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01907165's enrollment target sits among peer trials
21 145th of 199 higher than 53 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Implantable Microdevice In Primary Brain Tumors
RECRUITING · Early Phase 1
-
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
RECRUITING · Early Phase 1
-
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RECRUITING · Early Phase 1
-
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
RECRUITING · Early Phase 1
-
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI